Johnson & Johnson - JNJ STOCK NEWS

The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) published new data in Nature demonstrating that JNJ-1802, an antiviral candidate, is effective against dengue in non-human primates and mice. Following successful Phase 1 trials showing safety and tolerability in humans, JNJ-1802 is progressing to Phase 2 studies. The data revealed efficacy against all four dengue serotypes, particularly DENV-1 and DENV-2. Given the rising global dengue threat due to climate change, the findings emphasize the urgent need for antiviral solutions to combat this disease.

Johnson & Johnson (NYSE: JNJ) announced that its subsidiary Kenvue Inc. has priced an offering of senior unsecured notes totaling $7.75 billion. The notes have varying maturities and coupon rates, with the first series due 2025 at 5.500%. The proceeds will partially fund Kenvue's acquisition of Johnson & Johnson's Consumer Health Business. The offering is not contingent upon the separation's completion, expected around March 22, 2023. The notes will be guaranteed by Johnson & Johnson until the separation and registration of Kenvue's equity securities occur. The securities have not been registered under U.S. laws.

AtlantiCare has become the first healthcare system in the northeastern U.S. to implement the Optellum Virtual Nodule Clinic, enhancing early lung cancer diagnosis through AI technology. Located in New Jersey, this initiative is part of AtlantiCare's lung cancer program at the AtlantiCare Regional Medical Center. The platform aids in identifying and tracking at-risk patients, with the ability to biopsy concerning lesions early, potentially improving outcomes. With approximately 50 out of 300 patients flagged for surveillance, this partnership demonstrates the critical need for early-stage detection in lung cancer.

Johnson & Johnson (NYSE: JNJ) has appointed Dr. Paula A. Johnson, President of Wellesley College, to its Board of Directors. CEO Joaquin Duato welcomed her, citing her extensive knowledge in medical research and public health, which is expected to enhance the board’s expertise. Dr. Johnson expressed her commitment to improving health outcomes globally. With significant experience in academic medicine and leadership roles, including founding the Connors Center for Women’s Health, she is set to bring a valuable perspective as JNJ continues its mission of advancing healthcare.

Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global HealthCare Conference on Tuesday, March 14, at the Loews Miami Beach Hotel in Miami Beach, Florida. Company Group Chairmen Aldo Denti from DePuy Synthes and Peter Menziuso from Vision will represent the company at 10:15 a.m. (Eastern Time). Investors can access the live audio webcast on the Johnson & Johnson website. A replay of the audio webcast will be available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) has appointed Dr. John Reed as Executive Vice President of Pharmaceuticals, R&D, effective April 3, 2023. Dr. Reed brings over 35 years of experience in biomedical research, having previously served as Executive Vice President at Sanofi. He succeeds Dr. William Hait, who led the Pharmaceutical R&D organization on an interim basis since August 2022. CEO Joaquin Duato expressed confidence in Dr. Reed's capabilities to enhance innovation and competitiveness within the company. Dr. Reed has been instrumental in bringing multiple medicines to market during his career and aims to prioritize patient needs at Johnson & Johnson.

Biosense Webster, part of Johnson & Johnson MedTech, announced positive interim results from the inspIRE clinical study at the 28th Annual International AF Symposium. The study evaluated the safety and efficacy of the VARIPULSE™ Catheter and TRUPULSE™ Generator in treating recurrent paroxysmal atrial fibrillation (AF). Out of 226 enrolled patients across 13 centers, the study achieved an impressive 70.9% primary efficacy endpoint with 78.9% freedom from AF recurrence at 12 months. No serious adverse events were reported. The investigational device aims to provide a safer ablation technique, potentially reducing risks associated with traditional treatments.

Biosense Webster, part of Johnson & Johnson MedTech, announced positive results from the STELLAR study, presented at the 28th Annual International AF Symposium. This study evaluated the HELIOSTAR™ Balloon Ablation Catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AFib). Key findings include an acute pulmonary vein isolation (PVI) rate of 98.8%, with 67.7% primary effectiveness at 12 months. Furthermore, over 90% of participants remained free from repeat ablation after one year, with a clinical success rate of 77.7%. The HELIOSTAR™ is the first radiofrequency balloon catheter approved in EMEA for cardiac ablation.

Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 43^rd Annual HealthCare Conference on Tuesday, March 7, at the Boston Marriott Copley Place, Boston, MA. Joseph J. Wolk, Executive Vice President and Chief Financial Officer, is scheduled to represent the company at 11:10 a.m. Eastern Time. Investors and interested parties can access the live audio webcast on the company's website at www.investor.jnj.com. A replay of the audio webcast will be available approximately 48 hours after the event.